Anzeige
Mehr »
Freitag, 27.06.2025 - Börsentäglich über 12.000 News
Blockbuster-Bohrergebnisse: Gold-Antimon-Fund in Nevada trifft geopolitischen Nerv
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A14X6S | ISIN: US15870P3073 | Ticker-Symbol: 2I3
Frankfurt
27.06.25 | 15:29
6,000 Euro
-4,76 % -0,300
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
CHAMPIONS ONCOLOGY INC Chart 1 Jahr
5-Tage-Chart
CHAMPIONS ONCOLOGY INC 5-Tage-Chart
RealtimeGeldBriefZeit
6,3006,55021:27
6,3006,55021:24

Aktuelle News zur CHAMPIONS ONCOLOGY Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
28.04.Champions Oncology, Inc.: Champions Oncology Obtains Radioactive Materials License to Advance Comprehensive Radiotherapeutic Studies In-House200HACKENSACK, NJ / ACCESS Newswire / April 28, 2025 / Champions Oncology (NASDAQ:CSBR), a leader in translational oncology research, has been granted a license to use radioactive materials in preclinical...
► Artikel lesen
CHAMPIONS ONCOLOGY Aktie jetzt für 0€ handeln
28.04.Champions Oncology secures license for radionuclide studies1
28.04.Champions Oncology sichert Lizenz für Radionuklidstudien-
24.04.Champions Oncology, Inc.: Champions Oncology's Data Platform Gains Momentum through a Strategic Collaboration with Turbine452HACKENSACK, NJ / ACCESS Newswire / April 24, 2025 / Champions Oncology (NASDAQ:CSBR), a global leader in oncology R&D solutions, has announced a strategic collaboration with Turbine, the creators of...
► Artikel lesen
17.03.CHAMPIONS ONCOLOGY, INC. - 10-Q, Quarterly Report1
12.03.Champions Oncology target raised to $12 at Craig-Hallum1
11.03.Champions Oncology Non-GAAP EPS of $0.36 beats by $0.37, revenue of $17M beats by $4.07M2
11.03.CHAMPIONS ONCOLOGY, INC. - 8-K, Current Report2
11.03.Champions Oncology, Inc.: Champions Oncology Reports Record Quarterly Revenue of $17.0 Million Record Net Income of $4.5 Million289HACKENSACK, NJ / ACCESS Newswire / March 11, 2025 / Champions Oncology, Inc. (Nasdaq:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, today...
► Artikel lesen
06.03.Champions Oncology, Inc.: Champions Oncology to Announce Third Quarter Financial Results on Tuesday, March 11, 2025309HACKENSACK, NJ / ACCESS Newswire / March 6, 2025 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, will...
► Artikel lesen
18.02.Champions Oncology, Inc.: Champions Oncology Announces 17 Abstracts Accepted for Presentation at the 2025 American Association for Cancer Research Annual Meeting118HACKENSACK, NJ / ACCESS Newswire / February 18, 2025 / Champions Oncology Inc. (NASDAQ:CSBR), a global leader in preclinical oncology research and clinical specialty testing, today announced the acceptance...
► Artikel lesen
08.01.Champions Oncology erweitert sein klinisch-bioanalytisches Leistungsportfolio mit neuer Technologie und zusätzlichem Führungsexperten341HACKENSACK, NJ / ACCESSWIRE / 8. Januar 2025 / Champions Oncology, Inc. (NASDAQ: CSBR), eine führende technologiegestützte Organisation im Bereich der onkologischen Forschung, die spezielle Testdienstleistungen...
► Artikel lesen
08.01.Champions Oncology bolsters bioanalytical services2
08.01.Champions Oncology, Inc.: Champions Oncology Enhances Clinical Bioanalytical Services Portfolio with New Technology and Additional Leadership237HACKENSACK, NJ / ACCESSWIRE / January 8, 2025 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading technology-enabled oncology research organization with specialty testing services, is excited to announce...
► Artikel lesen
11.12.24Champions Oncology, Inc.: Champions Oncology Reports Quarterly Revenue of $13.5 Million Adjusted EBITDA of $1.1 Million277HACKENSACK, NJ / ACCESSWIRE / December 11, 2024 / Champions Oncology, Inc. (Nasdaq:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, today...
► Artikel lesen
05.12.24Champions Oncology, Inc.: Champions Oncology to Announce Second Quarter Financial Results on Wednesday, December 11, 2024283HACKENSACK, NJ / ACCESSWIRE / December 5, 2024 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, will...
► Artikel lesen
16.10.24Champions Oncology, Inc.: Champions Oncology Announces Agreement with Weill Cornell Medicine229HACKENSACK, NJ / ACCESSWIRE / October 16, 2024 / Champions Oncology, Inc. (Nasdaq:CSBR), a leader in the development of advanced preclinical oncology solutions, is pleased to announce a licensing agreement...
► Artikel lesen
11.09.24Champions Oncology, Inc.: Champions Oncology Reports Quarterly Revenue of $14.1 Million Adjusted EBITDA of $2.0 Million442HACKSENSACK, NJ / ACCESSWIRE / September 11, 2024 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, today...
► Artikel lesen
09.09.24Champions Oncology, Inc.: Champions Oncology to Announce First Quarter Financial Results on Wednesday, September 11, 2024374HACKENSACK, NJ / ACCESSWIRE / September 9, 2024 / Champions Oncology, Inc. (CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, will report...
► Artikel lesen
18.07.24Champions Oncology, Inc.: Champions Oncology Reports Quarterly Revenue of $14.0 Million415Annual Revenue of $50.2 Million HACKENSACK, NJ / ACCESSWIRE / July 18, 2024 / Champions Oncology, Inc. (Nasdaq:CSBR), a leader in the development of advanced preclinical oncology solutions, today announced...
► Artikel lesen
Weiter >>
21 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1